Crescent Biopharma, Inc.CBIONASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
114.29%
↑ 1118% above average
Average (39q)
-11.23%
Historical baseline
Range
High:114.29%
Low:-671.35%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 114.29% |
| Q2 2025 | -671.35% |
| Q1 2025 | 67.00% |
| Q4 2024 | 26.67% |
| Q3 2024 | 6.25% |
| Q2 2024 | 5.88% |
| Q1 2024 | -21.43% |
| Q4 2023 | 0.00% |
| Q3 2023 | -7.69% |
| Q2 2023 | 23.53% |
| Q1 2023 | 10.53% |
| Q4 2022 | -18.75% |
| Q3 2022 | 36.00% |
| Q2 2022 | 10.71% |
| Q1 2022 | 15.15% |
| Q4 2021 | 2.94% |
| Q3 2021 | -21.43% |
| Q2 2021 | 0.00% |
| Q1 2021 | 15.15% |
| Q4 2020 | -13.79% |
| Q3 2020 | 9.38% |
| Q2 2020 | -77.78% |
| Q1 2020 | 47.06% |
| Q4 2019 | -9.68% |
| Q3 2019 | 16.22% |
| Q2 2019 | -12.12% |
| Q1 2019 | -3.13% |
| Q4 2018 | -18.52% |
| Q3 2018 | -3.85% |
| Q2 2018 | 21.21% |
| Q1 2018 | -22.22% |
| Q4 2017 | -12.50% |
| Q3 2017 | 20.00% |
| Q2 2017 | 11.76% |
| Q1 2017 | 5.56% |
| Q4 2016 | -5.88% |
| Q3 2016 | 17.07% |
| Q2 2016 | -2.50% |
| Q1 2016 | 14.89% |
| Q4 2015 | -23.68% |